以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。
数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15
IBRX
18 atoms · 跨 4 天 · 首见 2026-04-20 · 最近 2026-05-22
三色: 🟦 fact 17 · 🟥 take 1 · stance ▲11/▼0/◆5
来源: X 18
时态: fresh:18
标签: 好数字:12 · 好信源:7 · 好观点:1 · 好思考:1
叙事 (narrative) (1)
- 2026-05-22 · 健康经济分析显示 ANKTIVA+BCG 治疗成本低于 TAR-200
ImmunityBio presented new ISPOR 2026 health economic analysis data. ANKTIVA + BCG showed lower costs versus TAR-200 treatment.
tags: 好思考 · → daily
事实 (fact) (17)
- 2026-05-19 ⭐ · FDA 目标行动日期
FDA assigns Jan. 6, 2027 target action date.
tags: 好数字·好信源 · → daily
value: date=2027-01-06
- 2026-05-19 ⭐ · QUILT 3.032 试验结果
QUILT 3.032 trial showed 58.2% 12-month disease-free survival rate.
tags: 好数字·好信源 · → daily
value: qty=58.2%
- 2026-05-19 ⭐ · NMIBC 患者比例
Approximately 85% of NMIBC patients present with papillary disease.
tags: 好数字·好信源 · → daily
value: qty=85%
- 2026-05-19 · FDA 接受 ANKTIVA 标签扩展申请
FDA Accepts $IBRX ImmunityBio’s ANKTIVA Label Expansion Application
tags: 好信源 · → daily
- 2026-05-19 · sBLA 目标
Filing targets BCG-unresponsive bladder cancer with papillary disease.
tags: 好信源 · → daily
- 2026-05-22 · 每避免一例膀胱切除术可节省成本
Cost savings per cystectomy avoided reached up to $151,438 at year two.
tags: 好数字 · → daily
value: qty=$151,438 · date=两年
- 2026-05-22 · 每例完全应答者节省成本
Analysis showed savings per complete responder exceeding $313,775 at year one.
tags: 好数字 · → daily
value: qty=$313,775 · date=一年
- 2026-05-22 · 完全应答率
Complete response rates were 49.6% for ANKTIVA versus 45.9% for TAR-200.
tags: 好数字 · → daily
value: qty=49.6% · date=N/A
- 2026-05-19 · NAI+BCG vs nadofaragene CR likelihood
NAI+BCG patients were 2x more likely to achieve complete response versus nadofaragene.
tags: 好数字 · → daily
value: qty=2x · direction=higher
- 2026-05-19 · median CR duration NAI+BCG
Median complete response duration reached 22.1 months versus 9.7 months.
tags: 好数字 · → daily
value: qty=22.1 months
- 2026-05-19 · cystectomy risk reduction NAI+BCG vs nadofaragene
NAI+BCG reduced cystectomy risk by 60% versus nadofaragene.
tags: 好数字 · → daily
value: qty=60% · direction=lower
- 2026-05-19 · 12-month CR rate NAI+BCG vs TAR-200
Compared with TAR-200, NAI+BCG showed numerically higher 12-month CR rates.
tags: 好数字 · → daily
- 2026-05-19 · treatment-related adverse events NAI+BCG vs TAR-200
NAI+BCG demonstrated significantly fewer treatment-related adverse events than TAR-200.
tags: 好数字 · → daily
- 2026-05-18 · 获得美国专利覆盖
ImmunityBio receives 5 issued U.S. patents covering ANKTIVA + BCG therapies. Patent protection extends through at least 2035.
tags: 好数字 · → daily
value: date=2035
- 2026-05-18 · 专利权利覆盖NMIBc治疗方法和商业试剂盒
Claims cover NMIBc treatment methods, dosing regimens, and commercial kits.
tags: 好信源 · → daily
- 2026-05-18 · 专利组合支持QUILT-2.005注册试验
Supports ongoing QUILT-2.005 registrational trial in bladder cancer.
tags: 好信源 · → daily
- 2026-04-20 · 被列入盈利周期最强的前20只股票
盈利周期最强的前20只股票及其未来营收预测 - 19. $IBRX：ImmunoGen Inc.（伊美诺基因，生物制药/ADC抗体偶联药物）
tags: 好观点 · → daily
时间轴 (近 20)
- 2026-05-22 ·
narrative · 健康经济分析显示 ANKTIVA+BCG 治疗成本低于 TAR-200 · → daily
- 2026-05-22 ·
fact · 每避免一例膀胱切除术可节省成本 · → daily
- 2026-05-22 ·
fact · 每例完全应答者节省成本 · → daily
- 2026-05-22 ·
fact · 完全应答率 · → daily
- 2026-05-19 ·
fact · NAI+BCG vs nadofaragene CR likelihood · → daily
- 2026-05-19 ·
fact · median CR duration NAI+BCG · → daily
- 2026-05-19 ·
fact · cystectomy risk reduction NAI+BCG vs nadofaragene · → daily
- 2026-05-19 ·
fact · 12-month CR rate NAI+BCG vs TAR-200 · → daily
- 2026-05-19 ·
fact · treatment-related adverse events NAI+BCG vs TAR-200 · → daily
- 2026-05-19 ·
fact · FDA 接受 ANKTIVA 标签扩展申请 · → daily
- 2026-05-19 ·
fact · sBLA 目标 · → daily
- 2026-05-19 ·
fact · FDA 目标行动日期 · → daily
- 2026-05-19 ·
fact · QUILT 3.032 试验结果 · → daily
- 2026-05-19 ·
fact · NMIBC 患者比例 · → daily
- 2026-05-18 ·
fact · 获得美国专利覆盖 · → daily
- 2026-05-18 ·
fact · 专利权利覆盖NMIBc治疗方法和商业试剂盒 · → daily
- 2026-05-18 ·
fact · 专利组合支持QUILT-2.005注册试验 · → daily
- 2026-04-20 ·
fact · 被列入盈利周期最强的前20只股票 · → daily
← 实体目录 · 系统日志